New Cavalry 9 Vaccine for Beef and Dairy Nine Clostridial ...
2
9 A Powerful Defense Against Nine Clostridial Diseases • Broadest spectrum available, including Tetanus • Demonstrated superior immune response • Demonstrated lowest reactivity • 2-mL subcutaneous administration • 10-, 25-, 50- and 125-dose bottles Cavalry ™ 9 Vaccine: Licensed Under Current USDA Potency and Safety Requirements 1 Based on USDA 9CFR requirements to demonstrate efficacy comparisons. 2 Based on USDA-accepted Schering-Plough Animal Health proprietary tests to demonstrate efficacy comparisons. 3 These results demonstrate the immune response of 3-month-old calves vaccinated with CAVALRY 9 versus Vision 8. It does not imply that the Vision 8 product, used in this study, fails to meet the USDA potency release testing, which is performed in rabbits and guinea pigs. 0.50 0.40 0.30 0.20 0.10 0.00 0.423 b 0.262 a 0.290 a Cavalry™ 9 Covexin® 8 Vision® 8 Clostridium septicum Efficacy Comparison Via ELISA Testing 2 Mean Antitoxin Antibody Response (U/mL) a,b Values with different superscripts are statistically different. Results represent the means of individual test results, not testing of serum pools. • CAVALRY 9 vaccination produced an antibody response statistically superior to COVEXIN 8 and Vision 8. Clostridium chauvoei Virulent Challenge: Bioequivalence to COVEXIN 8 2 0.20 0.16 0.12 0.08 0.04 0.00 0.15 a 0.12 a 0.09 b Cavalry™ 9 Covexin® 8 Vision® 8 Mean Antiflagellar Antibody Response (U/mL) a,b Values with different superscripts are statistically different. Results represent the means of individual test results, not testing of serum pools. • CAVALRY 9 vaccination produced an antibody response statistically superior to Vision 8. 15 12 9 6 3 0 12 a 12 a 2 b Cavalry™ 9 Covexin® 8 Vision® 8 Mean Antitoxin Antibody Response (U/mL) a,b Values with different superscripts are statistically different. Results represent the means of individual test results, not testing of serum pools. Clostridium haemolyticum Virulent Challenge: Bioequivalence to COVEXIN 8 2 • CAVALRY 9 vaccination produced an antibody response statistically superior to Vision 8. NEW Cavalry ™ 9 Vaccine for Beef and Dairy 100 80 60 40 20 0 Cavalry™ 9 Vision® 8 100% 40% Clostridium sordellii Potency Comparison 1 Percent of Animals *Results represent the testing of serum from individual cattle, not testing of serum pools. • CAVALRY 9 demonstrated potency superior to Vision 8 3 . 100 80 60 40 20 0 90% 100% 60% Cavalry™ 9 Covexin® 8 Vision® 8 Clostridium novyi Type B Potency Comparison 1 Percent of Animals *Results represent the testing of serum from individual cattle, not testing of serum pools. • CAVALRY 9 demonstrated potency superior to Vision 8. 3 100 80 60 40 20 0 Covexin® 8 Cavalry™ 9 100% 100% Clostridium tetani Potency Comparison 1 Percent of Animals *Results represent the testing of serum from individual cattle, not testing of serum pools. • CAVALRY 9 demonstrated potency equivalent to COVEXIN 8. 100 80 60 40 20 0 Cavalry™ 9 Vision® 8 85% 0% Clostridium perfringens Type D Potency Comparison 1 Percent of Animals *Results represent the testing of serum from individual cattle, not testing of serum pools. • CAVALRY 9 demonstrated potency superior to Vision 8 3 . 100 80 60 40 20 0 70% 70% 0% Cavalry™ 9 Covexin® 8 Vision® 8 Clostridium perfringens Types B and C Potency Comparison 1 Percent of Animals *Results represent the testing of serum from individual cattle, not testing of serum pools. • CAVALRY 9 demonstrated potency superior to Vision 8 3 .
Transcript of New Cavalry 9 Vaccine for Beef and Dairy Nine Clostridial ...
9 APowerfulDefenseAgainstNine ClostridialDiseases
•Broadestspectrumavailable,includingTetanus •Demonstratedsuperiorimmuneresponse •Demonstratedlowestreactivity•2-mLsubcutaneousadministration •10-,25-,50-and125-dosebottles
Cavalry™ 9 Vaccine: Licensed Under Current USDA Potency and Safety Requirements
1 Based on USDA 9CFR requirements to demonstrate efficacy comparisons.2 Based on USDA-accepted Schering-Plough Animal Health proprietary tests to demonstrate efficacy comparisons.
3 These results demonstrate the immune response of 3-month-old calves vaccinated with CAVALRY 9 versus Vision 8. It does not imply that the Vision 8 product, used in this study, fails to meet the USDA potency release testing, which is performed in rabbits and guinea pigs.
0.50
0.40
0.30
0.20
0.10
0.00
0.423b
0.262a0.290a
Cavalry™ 9Covexin® 8 Vision® 8
Clostridium septicumEfficacyComparisonViaELISATesting2
Mea
nA
ntito
xin
A
ntib
ody
Resp
onse
(U/m
L)
a,b Values with different superscripts are statistically different. Results represent the means of individual test results, not testing of serum pools.
• CAVALRY 9 vaccination produced an antibody response statistically superior to CoVexIn 8 and Vision 8.
Clostridium chauvoei VirulentChallenge:BioequivalencetoCoVExIn82
0.20
0.16
0.12
0.08
0.04
0.00
0.15a
0.12a
0.09b
Cavalry™ 9Covexin® 8 Vision® 8
Mea
nA
ntifl
agel
lar
Ant
ibod
yRe
spon
se(U
/mL)
a,b Values with different superscripts are statistically different. Results represent the means of individual test results, not testing of serum pools.
• CAVALRY 9 vaccination produced an antibody response statistically superior to Vision 8.
15
12
9
6
3
0
12a12a
2b
Cavalry™ 9Covexin® 8 Vision® 8
Mea
nA
ntito
xin
A
ntib
ody
Resp
onse
(U/m
L)
a,b Values with different superscripts are statistically different. Results represent the means of individual test results, not testing of serum pools.
Clostridium haemolyticumVirulentChallenge:BioequivalencetoCoVExIn82
• CAVALRY 9 vaccination produced an antibody response statistically superior to Vision 8.
New Cavalry™ 9 Vaccine for Beef and Dairy
100
80
60
40
20
0
Cavalry™ 9 Vision® 8
100%
40%
Clostridium sordellii PotencyComparison1
Perc
ento
fAni
mal
s
*Results represent the testing of serum from individual cattle, not testing of serum pools.
• CAVALRY 9 demonstrated potency superior to Vision 83.
100
80
60
40
20
0
90%
100%
60%
Cavalry™ 9Covexin® 8 Vision® 8
Clostridium novyi TypeBPotencyComparison1
Perc
ento
fAni
mal
s
*Results represent the testing of serum from individual cattle, not testing of serum pools.
• CAVALRY 9 demonstrated potency superior to Vision 8.3
100
80
60
40
20
0
Covexin® 8 Cavalry™ 9
100% 100%
Clostridium tetani PotencyComparison1
Perc
ento
fAni
mal
s
*Results represent the testing of serum from individual cattle, not testing of serum pools.
• CAVALRY 9 demonstrated potency equivalent to CoVexIn 8.
100
80
60
40
20
0
Cavalry™ 9 Vision® 8
85%
0%
Clostridium perfringens TypeDPotencyComparison1
Perc
ento
fAni
mal
s
*Results represent the testing of serum from individual cattle, not testing of serum pools.
• CAVALRY 9 demonstrated potency superior to Vision 83.
100
80
60
40
20
0
70%70%
0%
Cavalry™ 9Covexin® 8 Vision® 8
Clostridium perfringens TypesBandCPotencyComparison1
Perc
ento
fAni
mal
s
*Results represent the testing of serum from individual cattle, not testing of serum pools.
• CAVALRY 9 demonstrated potency superior to Vision 83.
Applied Innovation in Vaccines
Copyright © 2007, Schering-Plough Animal Health Corporation. All rights reserved. Cavalry is a trademark and Covexin is a registered trademark of Schering-Plough Animal Health Corporation. The trademarks depicted within this piece are owned by their respective companies. SPAH-CAV-02P-R.
Cavalry™ 9 Vaccine: Less Reactive Than Leading Clostridial Products
• CAVALRY 9 injection site reactions following the second vaccination were smaller and less pronounced than reactions caused by other vaccines.
• Far fewer calves experienced injection site reactions with CAVALRY 9 vaccine than with other vaccines.
PercentageofCalveswithInjectionSiteReactionsPostFIRSTVaccination
0 10 20 30 40 50 60 70
100
90
80
70
60
50
40
30
20
10
0
Cavalry™ 9Ultrabac® 7 Caliber® 7Vision® 8 Alpha-7™
Perc
ento
fCal
ves
with
Rea
ctio
n
DaysPostVaccination
• CAVALRY 9 vaccine injection site reactions resolved more quickly than reactions caused by other vaccines.
MeanInjectionSiteReactionsAfterFIRSTVaccination
0 10 20 30 40 50 60 70
25
20
15
10
5
0
Cavalry™ 9Ultrabac® 7 Caliber® 7Vision® 8 Alpha-7™
Size
ofL
ump
(cub
icc
m)
DaysPostVaccination
MeanInjectionSiteReactionsAfterSEConDVaccination
0 5 10 15 20 25 30 35
70
60
50
40
30
20
10
0
Cavalry™ 9Ultrabac® 7 Caliber® 7Vision® 8
Mea
nRe
actio
n(c
ubic
cm
)
DaysPostVaccination
PercentageofCalveswithInjectionSiteReactionsPostSEConDVaccination
0 5 10 15 20 25 30 35
100
90
80
70
60
50
40
30
20
10
0
Cavalry™ 9Ultrabac® 7 Caliber® 7Vision® 8
Perc
ento
fCal
ves
with
Rea
ctio
n
DaysPostVaccination
• Injection site reactions typically are more pronounced after a second dose. Those from CAVALRY 9 vaccine resolved in about two weeks, much more quickly than reactions caused by other vaccines.
